利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.024 秒)

    Method of treating glaucoma using rasagiline
    1.
    发明申请
    Method of treating glaucoma using rasagiline 审中-公开
    使用雷沙吉兰治疗青光眼的方法

    公开(公告)号：US20090062400A1

    公开(公告)日：2009-03-05

    申请号：US12231601

    申请日：2008-09-03

    申请人： Laurence Oron ,  Cheryl Fitzer-Attas ,  Ron Neumann

    发明人： Laurence Oron ,  Cheryl Fitzer-Attas ,  Ron Neumann

    IPC分类号： A61K31/136 ,  A61P27/06

    CPC分类号： A61K31/136

    摘要： Disclosed is a method of reducing glaucoma in a subject afflicted with glaucoma, comprising administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptably salt thereof effective to reduce glaucoma.

    摘要翻译： 公开了减轻患有青光眼的受试者的青光眼的方法，其包括给予受试者一定量的有效降低青光眼的R（+） - N-炔丙基-1-氨基茚满或其药学上可接受的盐。

    Tumor associated antigen peptides and use of same as anti-tumor vaccines
    2.
    发明授权
    Tumor associated antigen peptides and use of same as anti-tumor vaccines 失效
    肿瘤相关抗原肽及其与抗肿瘤疫苗的使用

    公开(公告)号：US07960507B2

    公开(公告)日：2011-06-14

    申请号：US12844663

    申请日：2010-07-27

    申请人： Lea Eisenbach ,  Boaz Tirosh ,  Erez Bar-Haim ,  Adrian Paz ,  Matityahu Fridkin ,  Cheryl Fitzer-Attas ,  Arthur Machlenkin ,  Esther Tzehoval

    发明人： Lea Eisenbach ,  Boaz Tirosh ,  Erez Bar-Haim ,  Adrian Paz ,  Matityahu Fridkin ,  Cheryl Fitzer-Attas ,  Arthur Machlenkin ,  Esther Tzehoval

    IPC分类号： C07K16/00

    CPC分类号： C12N9/6445 ,  A61K39/00 ,  A61K48/00 ,  C07K14/47 ,  C07K14/4727 ,  C07K14/705 ,  C12N9/16

    摘要： The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

    摘要翻译： 本发明涉及肿瘤相关抗原（TAA）肽及其使用方法，其编码相同的多核苷酸和与抗肿瘤疫苗相同的细胞。 更具体地说，本发明涉及衍生自Uroplatinin Ia，Ib，II和III，前列腺特异性抗原（PSA），前列腺酸性磷酸酶（PAP）和前列腺特异性膜抗原（PSMA），BA-46（Lactadherin ），粘蛋白（MUC-1）和细胞因子来源的生长因子（CRIPTO-1），以及其与抗肿瘤疫苗的用途预防或治愈膀胱，前列腺，乳腺癌或其他癌症，特别是癌症。 最特别地，本发明涉及可由HLA-A2分子呈递给免疫系统的肿瘤相关抗原肽。

    COMBINATION OF RASAGILINE AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE
    3.
    发明申请
    COMBINATION OF RASAGILINE AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE 审中-公开
    用于治疗特殊性亨廷顿病的神经损伤性疾病的RASAGILINE和PRIDOPIDINE的组合

    公开(公告)号：US20140088145A1

    公开(公告)日：2014-03-27

    申请号：US14040579

    申请日：2013-09-27

    申请人： Michael Hayden ,  Cheryl Fitzer-Attas

    发明人： Michael Hayden ,  Cheryl Fitzer-Attas

    IPC分类号： A61K31/451 ,  A61K31/137

    CPC分类号： A61K31/451 ,  A61K31/135 ,  A61K31/137 ,  A61K2300/00

    摘要： This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease, comprising administering to the patient rasagiline as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising rasagiline and pridopidine for treating a patient afflicted with a neurodegenerative disorder. This invention also provides rasagiline for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder. This invention further provides use of rasagiline and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder.

    摘要翻译： 本发明提供了治疗患有神经退行性疾病例如亨廷顿舞蹈病的患者的方法，其包括向患者施用雷沙吉兰作为与特鲁替丁或与其结合的附加疗法。 本发明还提供了一种包含药物组合物和药物组合物，其包含用于治疗患有神经变性疾病的患者的雷沙吉兰和格列方啶。 本发明还提供雷沙吉兰作为附加疗法或与格列吡啶联合用于治疗患有神经变性疾病的患者。 本发明进一步提供了雷沙吉兰和格列吡啶在制备用于治疗患有神经变性疾病的患者的组合中的用途。

    Tumor associated antigen peptides and use of same as anti-tumor vaccines
    4.
    发明授权
    Tumor associated antigen peptides and use of same as anti-tumor vaccines 失效
    肿瘤相关抗原肽及其与抗肿瘤疫苗的使用

    公开(公告)号：US07795224B2

    公开(公告)日：2010-09-14

    申请号：US12326675

    申请日：2008-12-02

    申请人： Lea Eisenbach ,  Erez Bar-Haim ,  Adrian Paz ,  Matityahu Fridkin ,  Cheryl Fitzer-Attas

    发明人： Lea Eisenbach ,  Erez Bar-Haim ,  Adrian Paz ,  Matityahu Fridkin ,  Cheryl Fitzer-Attas

    IPC分类号： A61K38/00

    CPC分类号： C12N9/6445 ,  A61K39/00 ,  A61K48/00 ,  C07K14/47 ,  C07K14/4727 ,  C07K14/705 ,  C12N9/16

    摘要： The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

    摘要翻译： 本发明涉及肿瘤相关抗原（TAA）肽及其使用方法，其编码相同的多核苷酸和与抗肿瘤疫苗相同的细胞。 更具体地说，本发明涉及衍生自Uroplatinin Ia，Ib，II和III，前列腺特异性抗原（PSA），前列腺酸性磷酸酶（PAP）和前列腺特异性膜抗原（PSMA），BA-46（Lactadherin ），粘蛋白（MUC-1）和细胞因子来源的生长因子（CRIPTO-1），以及其与抗肿瘤疫苗的用途预防或治愈膀胱，前列腺，乳腺癌或其他癌症，特别是癌症。 最特别地，本发明涉及可由HLA-A2分子呈递给免疫系统的肿瘤相关抗原肽。

    COMBINATION OF RASAGILINE AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE
    7.
    发明申请
    COMBINATION OF RASAGILINE AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE 审中-公开
    用于治疗特殊性亨廷顿病的神经损伤性疾病的RASAGILINE和PRIDOPIDINE的组合

    公开(公告)号：US20150216850A1

    公开(公告)日：2015-08-06

    申请号：US14426339

    申请日：2013-09-27

    申请人： Michael HAYDEN ,  Cheryl FITZER-ATTAS

    发明人： Michael Hayden ,  Cheryl Fitzer-Attas

    IPC分类号： A61K31/451 ,  A61K31/135

    CPC分类号： A61K31/451 ,  A61K31/135 ,  A61K31/137 ,  A61K2300/00

    摘要： This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease, comprising administering to the patient rasagiline as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising rasagiline and pridopidine for treating a patient afflicted with a neurodegenerative disorder. This invention also provides rasagiline for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder. This invention further provides use of rasagiline and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder.

    摘要翻译： 本发明提供了治疗患有神经退行性疾病例如亨廷顿舞蹈病的患者的方法，其包括向患者施用雷沙吉兰作为与特鲁替丁或与其结合的附加疗法。 本发明还提供了一种包含药物组合物和药物组合物，其包含用于治疗患有神经变性疾病的患者的雷沙吉兰和格列方啶。 本发明还提供雷沙吉兰作为附加疗法或与格列吡啶联合用于治疗患有神经变性疾病的患者。 本发明进一步提供了雷沙吉兰和格列吡啶在制备用于治疗患有神经变性疾病的患者的组合中的用途。

    TUMOR ASSOCIATED ANTIGEN PEPTIDES AND USE OF SAME AS ANTI-TUMOR VACCINES
    9.
    发明申请
    TUMOR ASSOCIATED ANTIGEN PEPTIDES AND USE OF SAME AS ANTI-TUMOR VACCINES 失效
    肿瘤相关抗原肽及其作为抗肿瘤疫苗的用途

    公开(公告)号：US20090136462A1

    公开(公告)日：2009-05-28

    申请号：US12326675

    申请日：2008-12-02

    申请人： Lea EISENBACH ,  Erez Bar-Haim ,  Adrian Paz ,  Matityahu Fridkin ,  Cheryl Fitzer-Attas

    发明人： Lea EISENBACH ,  Erez Bar-Haim ,  Adrian Paz ,  Matityahu Fridkin ,  Cheryl Fitzer-Attas

    IPC分类号： A61K35/12 ,  C07K7/06 ,  A61K38/08

    CPC分类号： C12N9/6445 ,  A61K39/00 ,  A61K48/00 ,  C07K14/47 ,  C07K14/4727 ,  C07K14/705 ,  C12N9/16

    摘要： The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

    摘要翻译： 本发明涉及肿瘤相关抗原（TAA）肽及其使用方法，其编码相同的多核苷酸和与抗肿瘤疫苗相同的细胞。 更具体地说，本发明涉及衍生自Uroplatinin Ia，Ib，II和III，前列腺特异性抗原（PSA），前列腺酸性磷酸酶（PAP）和前列腺特异性膜抗原（PSMA），BA-46（Lactadherin ），粘蛋白（MUC-1）和细胞因子来源的生长因子（CRIPTO-1），以及其与抗肿瘤疫苗的用途预防或治愈膀胱，前列腺，乳腺癌或其他癌症，特别是癌症。 最特别地，本发明涉及可由HLA-A2分子呈递给免疫系统的肿瘤相关抗原肽。